Search the Newsreel

BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating

BofA Securities has reiterated its Buy rating on Novartis AG (NVS.US). This endorsement suggests the firm's continued confidence in the pharmaceutical company's financial prospects and market performance. Investors will likely view this as a positive signal for Novartis.

Company News for July 22, 2026

Novartis AG's NVS shares grew 2.9% after reporting second-quarter 2026 revenues of $14.41 billion, beating the Zacks Consensus Estimate of $13.95 billion. Shares of General Motors Company GM gained 4.9% after reporting second-quarter 2026 earnings of $3.57 per share, beating the Zacks Consensus Estimate …

NOVARTIS AG : JP Morgan reaffirms its Buy rating

JP Morgan has reaffirmed its "Buy" rating for Novartis AG, with analyst Richard Vosser maintaining a positive recommendation. The target price for the pharmaceutical company is unchanged at CHF 135. This update comes amidst other recent analyst ratings, including Deutsche Bank maintaining a "Buy" …

Novartis: The Buy Thesis Is Back (Rating Upgrade)

Novartis Number of Employees 2026 | Employee Count & Headcount Data

Novartis AG had approximately 75,497 employees worldwide as of March 2026, representing a 1.2% decline from 2023. The company is actively hiring, with 2,864 job postings in 2026, though hiring velocity has slowed. The largest employee concentrations are in the United States, India, and …

Novartis AG 2Q Net Pft $3.3B

Novartis AG announced its second-quarter net profit of $3.3 billion. This figure indicates the company's financial performance during that period.

AI is helping speed up the timelines of drug discovery, Novartis CEO says

Novartis stock (NVS) gets a lift higher on Tuesday after topping second quarter earnings estimates. Novartis CEO Vas Narasimhan sits down with Julie Hyman to talk more about the pharma giant's research into utilizing AI to aid in new drug discovery. Video Transcript 00:00 …

Novartis Profit Beats Estimates as Entresto Sales Plunge 50%

This article first appeared on GuruFocus. Novartis AG (NYSE:NVS), a Swiss pharmaceutical company focused on innovative medicines, reported stronger-than-expected second-quarter results as newer cancer treatments helped offset declining sales from its former blockbuster heart drug Entresto. Earnings excluding certain items remained unchanged at $5.94 …

Novartis AG Stock (NVS) Moved Up by 3.42% on Jul 21: Key Drivers Unveiled

Novartis AG (NVS) stock increased by 3.42% on July 21st, driven by a strong quarterly earnings report that surpassed analyst expectations and an upgraded full-year guidance. The company's performance was bolstered by growth in its oncology and immunology segments, successful cost-saving synergies from restructuring, …

Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well

Swiss pharma giant Novartis AG NVS reported second-quarter core earnings per share (excluding one-time charges) of $2.41, which comfortably beat the Zacks Consensus Estimate of $2.20. The figure was, however, down from $2.42 reported a year ago due to lower core net income. Revenues …

Novartis climbs on upbeat drug sales as key readouts loom

Novartis reported stronger-than-expected second-quarter sales and core operating income, driven by newer "priority brands" like Kisqali, Kesimpta, and Scemblix, despite a significant drop in revenue for its former top-seller, Entresto, due to generic competition. The company is preparing for upcoming patent expirations on several …

Novartis Q2 Earnings Call Highlights

Key Points Interested in Novartis AG? Here are five stocks we like better. Novartis returned to sales growth in Q2 2026, with net sales up 1% in constant currency to $14.4 billion and free cash flow of $5.6 billion. The company reaffirmed its full-year …

Novartis Is On The Rise. But So, Too, Are Its Generic Rivals.

Novartis stock popped Tuesday on a solid second-quarter report, despite feeling continued heat from generic rivals for big-name drugs. Continue Reading

Novartis Q2 2026 Earnings Call Transcript

Novartis reported a 1% net sales growth in Q2 2026, reaching $14.4 billion, with core operating income remaining flat at $5.9 billion. The company reaffirmed its full-year 2026 guidance, expecting low single-digit net sales growth and a decline in core operating income, driven by …

Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Novartis (NVS) reported revenue of $14.41 billion, up 2.5% over the same period last year. EPS came in at $2.41, compared to $2.42 in the year-ago quarter. The reported revenue represents a surprise of +3.3% over the Zacks …

Novartis Q2 2026 earnings beat as cancer, MS drugs drive growth

Novartis reported second-quarter net sales of $14.4 billion on Tuesday, up 3% in dollar terms and 1% in constant currencies, as strong demand for cancer and multiple sclerosis treatments helped the Swiss drugmaker return to sales growth despite a steep drop in its top-selling …

U.S. stocks set for higher open as strong earnings boost market sentiment: Dow Jones, S&P, Nasdaq, Wall Street Futures

Wall Street bull ©Shutterstock Earnings optimism supports pre-market gains U.S. stock futures pointed to a firmer open on Tuesday as investors looked to recover from the previous session's decline, with upbeat corporate earnings encouraging buying across several sectors. Market sentiment improved after a series …

Novartis Bounds For Buy Point. Why Shares Are On The Rise.

Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx. Continue Reading

Novartis Earnings Beat, Cash Flow Weakens

This article first appeared on GuruFocus. Novartis (NYSE:NVS) beat second-quarter expectations on both revenue and earnings, while reaffirming its full-year 2026 outlook despite weaker free cash flow. The Swiss drugmaker reported adjusted earnings of $2.41 per share, beating estimates by $0.26. Revenue rose 2.6% …

Novartis Q2 profits recover as revenue mantle passes to newer medicines

Despite a lacklustre start to the year, Novartis seems to have overcome its financial slump, reporting operating profits in Q2 that exceeded analyst expectations. The Swiss drugmaker's core operating income for the quarter was $5.94bn, representing flat year-over-year growth. However, this was ahead of …

Novartis CEO Vas Narasimhan says 'no change of plans'

Novartis CEO Vas Narasimhan confirmed his commitment to leading the company through its next phase of growth, despite a period of significant patent expiries. He expressed anticipation for upcoming drug trial data announcements and new product launches, highlighting a focus on AI transformation. Narasimhan …

Novartis returns to sales growth in Q2 as newer medicines offset generic pressure (NVS)

Researcher with pipette ©National Institutes of Health New therapies drive quarterly revenue increase Novartis AG (NYSE:NVS) reported higher second-quarter sales on Tuesday, with strong demand for its newer medicines helping to offset the continued impact of generic competition and supporting the company's decision to …

Earnings call transcript: Novartis tops Q2 2026 forecasts as shares rise

Novartis reported a 1% net sales growth in Q2 2026, reaching $14.4 billion, with core operating income remaining flat at $5.9 billion. The company reaffirmed its full-year 2026 guidance, expecting low single-digit net sales growth and a decline in core operating income, driven by …

Earnings Snapshot: Novartis Q2 tops earnings and revenue estimates; full-year 2026 outlook reaffirmed

[https://static.seekingalpha.com/uploads/2026/7/21/saupload_Screenshot_2026-07-21_120006.png] MORE ON NOVARTIS * Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon [https://seekingalpha.com/article/4920275-novartis-pipeline-building-continues-pelacarsen-readout-coming-soon] * Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts [https://seekingalpha.com/article/4919803-novartis-hold-on-continued-generic-erosion-need-for-2nd-half-2026-catalysts] * Novartis Plays Long Game With Antares Deal - Meaning Near-Term Upside Unlikely [https://seekingalpha.com/a

Novartis beats top-line and bottom-line estimates; reaffirms FY26 outlook

* Novartis press release [https://www.novartis.com/sites/novartis_com/files/q2-2026-media-release-en.pdf] (NVS [https://seekingalpha.com/symbol/NVS]): Q2 Non-GAAP EPS of $2.41 beats by $0.26. * Revenue of $14.41B (+2.6% Y/Y) beats by $350M. * Q2 free cash flow was USD 5.6 billion (-12% USD). * FULL-YEAR 2026 GUIDANCE REAFFIRMED: Net sales expected to …

Novartis Q2 Profit Drops, Net Sales Rise; Reaffirms FY26 Guidance

(RTTNews) - Swiss pharmaceutical major Novartis AG (NVS, NOVN.SW) reported Tuesday lower profit in its second quarter, despite higher net sales and volume growth. Further, the company said it continues to expect fiscal 2026 core operating income to decline low single-digit and net sales …

Novartis Pharma AG

Novartis reported sales growth in Q2 2026, driven by key brands like Kisqali, Kesimpta, and Scemblix, and reaffirmed its full-year guidance for low single-digit net sales growth. The company also highlighted significant pipeline advancements, including new approvals for Rhapsido and Itvisma, and progress in …

Novartis Earnings Preview: Can New Medicines Offset Generic Pressure and Growing U.S. Pricing Risks?

Novartis is entering its Q2 earnings call facing significant pressure from generic competition and U.S. drug pricing reforms, having already experienced weaker Q1 revenues. Investors will closely watch whether new growth drivers like Kisqali, Pluvicto, and Kesimpta can continue to offset losses from patent …

Novartis pipeline faces critical test as upcoming trial results underpin growth outlook

Novartis is facing a critical period as upcoming trial results for three late-stage medicines will determine its long-term growth. These trials for pelacarsen, remibrutinib, and del-desiran are crucial for supporting the company's premium market valuation and offsetting future patent expirations, with analysts projecting these …

Novartis Drug Pipeline Faces Test Amid Valuation Premium Concerns

Novartis's premium valuation depends heavily on the upcoming trial results for three key experimental drugs: pelacarsen, remibrutinib, and del-desiran. These drugs are crucial for offsetting an anticipated $4 billion loss from generic competition, particularly for Entresto. Analysts suggest that at least two of these …

Novartis faces drug pipeline test with valuation premium in focus

By Bhanvi Satija LONDON, July 20 (Reuters) - Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year seen as vital to justifying the Swiss ‌drugmaker's premium valuation. Analysts say …

Earnings To Watch: Novartis AG (XSWX:NOVN) Reports Q2 2026 Result

Novartis AG (XSWX:NOVN) is scheduled to release its Q2 2026 earnings on July 21, 2026, with an estimated revenue of $11.34 billion and earnings of $1.40 per share. While full-year 2026 estimates for revenue and earnings have slightly declined, 2027 estimates show an increase. …

Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?

Novartis recently received traditional FDA approval for Fabhalta (iptacopan) to treat primary IgA nephropathy, converting its prior accelerated approval. This approval is based on strong clinical trial data showing Fabhalta slows kidney function decline, reinforcing Novartis's growing nephrology portfolio which also includes Vanrafia and …

This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval

The FDA has granted full approval to Novartis's oral medication Fabhalta (iptacopan) to slow kidney function decline in adult patients with primary immunoglobulin A nephropathy (IgAN). This treatment could delay the need for dialysis or transplant for at-risk individuals. The decision was based on …

Novartis wins full FDA approval for kidney disease drug Fabhalta in IgA nephropathy

Novartis has received full FDA approval for its kidney disease drug Fabhalta (iptacopan), specifically for primary immunoglobulin A nephropathy, also known as Berger disease. Fabhalta is an oral Factor B inhibitor designed to treat this autoimmune condition. This approval marks a significant step for …

Novartis Receives Full FDA Approval for Kidney Disease Therapy

Novartis has received full FDA approval for its kidney disease therapy, Fabhalta (iptacopan), for treating primary immunoglobulin A nephropathy (IgAN). Clinical trials showed significant improvement in estimated glomerular filtration rate over two years, solidifying its efficacy in slowing kidney function decline. This approval, coupled …